Compare Moderna, Inc. (MRNA) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Occidental Petroleum Corporation — how do they compare? Moderna, Inc. trades at $196.71 (market cap $78.44B), while Occidental Petroleum Corporation trades at $60.14 (market cap $58.19B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Occidental Petroleum Corporation pays a 1.92% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Occidental Petroleum Corporation for 92 Days on average.
| MRNA | OXY | |
|---|---|---|
Market Cap | $78.44B | $58.19B |
Volume | 14,597,511 | 7,092,290 |
Sector | Health | Energy |
52-Week High | $203.46 | $66.24 |
52-Week Low | $22.36 | $38.92 |
Typical Hold Time | 59 Days | 92 Days |
Enterprise Value | $74.59B | $76.95B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
Occidental Petroleum (OXY) trades at $60.28, up 3.34% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by a consensus price target of $71.40, indicating potential upside. Recent news highlights Goldman Sachs' upgrade to Buy, citing cash flow targets and debt reduction. Revenue has declined from $36.6B in 2022 to $21.6B in 2025, but net income margin remains healthy at 30.32%, and the company maintains a solid balance sheet with manageable debt levels.
OXY presents a favorable risk-reward profile with analyst optimism and operational efficiency, though exposure to oil price volatility and competitive pressures pose risks. The upcoming Q3 2026 earnings report on November 9 is a key catalyst. Institutional sentiment is positive, with 52% of analysts rating it Buy. Investors should weigh the stock's valuation appeal against macroeconomic headwinds affecting the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
